Clinical Trial Update November 2026

Clinical Report: Clinical Trial Update November 2026

Overview

Retinal Physician’s November 2026 update lists clinical trials in age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis. The supplied excerpt details several new dry AMD studies, including trials in geographic atrophy (GA), imaging, dietary intervention, and anesthesia for intravitreal injections; it also notes two terminated studies.

Background

AMD, DME, RVO, and uveitis are retinal or inflammatory eye conditions represented in the trial listing. The update provides study purposes, designs, planned enrollment, sponsors, and contact information where supplied. The excerpt identifies GA secondary to AMD as the focus of multiple listed studies, spanning phase 1 through phase 3 and including interventional and imaging approaches. It is a trial directory rather than a report of completed efficacy or safety results.

Data Highlights

Study	Design	Planned enrollment	Purpose
OCU410 for GA secondary to dry AMD	Phase 3; multicenter, randomized, controlled, assessor-blinded, adaptive	237	Assess efficacy, safety, and tolerability
Adaptive optics scanning light ophthalmoscopy and microperimetry substudy	Pilot comparative imaging study	10	Evaluate whether OCT, AOSLO, and microperimetry can relate retinal structural changes to vision
GLOVE dietary intervention	Nonrandomized, unmasked, single-group	32	Test dietary intervention effects on glycemic control and carotenoid levels in intermediate AMD
Oral STL303 in GA	Phase 2; multicenter, randomized, double-masked, placebo-controlled, parallel-group, dose-range finding	300	Assess efficacy and safety
FWY003 in GA	Phase 2; randomized, multicenter, double-masked, prospective	272	Characterize dose-response relationship
QUELL anesthesia study	Phase 4; multicenter, randomized, double-masked	236	Compare chloroprocaine HCl ophthalmic gel 3% with proparacaine 0.5% plus subconjunctival lidocaine for intravitreal injection anesthesia
ABF-101	Phase 1; single- and multiple-ascending-dose	68	Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and participants with AMD
CTx001 (Opti-GAIN)	Phase 1/2; randomized, open-label	75	Evaluate safety, tolerability, and efficacy after a single subretinal injection for GA secondary to AMD

Key Findings

The update identifies RO7669330, a study in participants with GA secondary to AMD, as terminated.
The update identifies the TITAN study of REGN7041 for active noninfectious uveitis in adults as terminated.
The new OCU410 study is a phase 3 trial with planned enrollment of 237 participants and an assessor-blinded adaptive design.
Several listed GA studies are phase 1, phase 1/2, or phase 2 investigations, including studies of oral STL303, FWY003, ABF-101, and subretinal CTx001.
The listed GLOVE study is a nonrandomized, unmasked, single-group dietary intervention in early to intermediate AMD, with planned enrollment of 32.
The QUELL phase 4 study plans to enroll 236 participants and compares two anesthesia regimens for intravitreal injection procedures.

Clinical Implications

The listing supplies trial design and enrollment information that may help clinicians identify studies relevant to patients with GA or other conditions covered by the update. It does not provide trial outcomes, so efficacy and safety conclusions cannot be drawn from this excerpt.

Conclusion

The November 2026 update documents a range of ongoing and newly listed clinical investigations, particularly in GA secondary to AMD. The supplied material is a study directory and reports no results for the listed trials.